/stocks — the workspaceLOADING
All ICLRSEC filings, by type → · Earnings date & implied move · Search inside filings
ICON PLC (ICLR) is a services-commercial physical & biological research company. Piotroski F-Score 6/8. 15 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind ICLR’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from ICLR’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on ICLR plus an auto-SWOT — built from ICLR's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ICLR using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has ICLR been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
Projected from ICLR's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentICLR files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| Brave Warrior Advisors (Glenn Greenberg) | $331.6M | 8.2% of portfolio |
Total return including reinvested dividends, from ICLR’s adjusted closing prices. Past return is not a forecast and not investment advice.
No lawmaker has disclosed a trade in ICLR under the STOCK Act.
Every figure is from ICLR’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
| Clerkin Nigel Bernard JohnChief Financial Officer | SELL | $372K | view → |
| CLIMAX JOHN DRDirector | SELL | $138K | view → |
| Grais LindaDirector | SELL | $138K | view → |
| McCague Eugene PacelliDirector | SELL | $138K | view → |
| Murphy Ronan MartinDirector | SELL | $138K | view → |
| Murray CiaranDirector | SELL | $440K | view → |
| O'Neill JulieDirector | SELL | $150K | view → |
| Whitaker Anne ClemDirector | SELL | $138K | view → |
These two signals are 133 days apart. Form 4 is filed within two business days of the trade; 13F is filed up to 45 days after quarter end and describes positions as they stood on that date. Agreement between them is not confirmation — the funds may have moved months before the insiders did, or the other way round. Read them as two separate observations that happen to point the same way, never as one signal backing up another.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.